Janux Therapeutics (JANX) Interest Coverage Ratio (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Interest Coverage Ratio of 1.2 for Q1 2026, down 351.23% year-over-year from 0.48 in Q1 2025, and down 263.86% quarter-over-quarter from 0.33 in Q3 2025.
Janux Therapeutics (JANX) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Interest Coverage Ratio for 7 consecutive years, with 1.2 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 351.23% year-over-year to 1.2; the TTM figure through Mar 2026 stood at 5.51 (down 536.12% YoY), while the FY2025 annual figure was 5.33, down 1848.8% from the prior year.
- Interest Coverage Ratio slipped to 1.2 in Q1 2026 per JANX's latest filing, from 0.33 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 0.05 in Q2 2024 and bottomed at 53.1 in Q4 2022.
- Historically, Interest Coverage Ratio has averaged 4.22 across 5 years, with a median of 0.46 in 2022.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio soared 91.5% — and 2025, when it slumped 849.0%.
- Janux Therapeutics' Interest Coverage Ratio stood at 53.1 in 2022, then soared by 98.02% to 1.05 in 2023, then soared by 89.1% to 0.11 in 2024, then slumped by 188.57% to 0.33 in 2025, then tumbled by 263.86% to 1.2 in 2026.
- Business Quant data shows JANX's Interest Coverage Ratio at 1.2 in Q1 2026, 0.33 in Q3 2025, and 0.46 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | -0.82 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.82 |
| Mar 31, 2026 | -1.20 |
| Sep 30, 2025 | -0.33 |
| Jun 30, 2025 | -0.46 |
| Mar 31, 2025 | -0.27 |
| Sep 30, 2024 | -0.11 |
| Jun 30, 2024 | -0.05 |
| Mar 31, 2024 | -0.08 |
| Sep 30, 2023 | -1.05 |
| Jun 30, 2023 | -0.57 |
| Mar 31, 2023 | -0.54 |
| Dec 31, 2022 | -53.10 |
| Sep 30, 2022 | -0.48 |
| Jun 30, 2022 | -0.46 |
| Mar 31, 2022 | -0.39 |
| Sep 30, 2021 | -0.15 |
| Dec 31, 2020 | 8.03 |
| Jun 30, 2020 | -10.15 |